elegrobart

all catalysts(0)

nothing on the calendar yet

News(3)

• Viridian may have edge over Amgen in eye drug showdown, analysts argue
  The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
  biopharma_dive · 1mo ago
• Viridian data lift prospects for thyroid eye disease drug
  Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.
  biopharma_dive · 3mo ago
• STAT+: Are analysts too quick to gloss over Lilly’s liver case?
  Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
  stat · 3mo ago